Integra LifeSciences Statistics
Share Statistics
Integra LifeSciences has 77.71M
shares outstanding. The number of shares has increased by -2.01%
in one year.
| Shares Outstanding | 77.71M |
| Shares Change (YoY) | -2.01% |
| Shares Change (QoQ) | 0.07% |
| Owned by Institutions (%) | 90.64% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 613 |
| FTD / Avg. Volume | 0.06% |
Short Selling Information
The latest short interest is 3.81M, so 4.9% of the outstanding
shares have been sold short.
| Short Interest | 3.81M |
| Short % of Shares Out | 4.9% |
| Short % of Float | 7.99% |
| Short Ratio (days to cover) | 4.99 |
Valuation Ratios
The PE ratio is -251.52 and the forward
PE ratio is 5.11.
Integra LifeSciences's PEG ratio is
2.28.
| PE Ratio | -251.52 |
| Forward PE | 5.11 |
| PS Ratio | 1.08 |
| Forward PS | 0.5 |
| PB Ratio | 1.13 |
| P/FCF Ratio | 69.96 |
| PEG Ratio | 2.28 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Integra LifeSciences.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.17,
with a Debt / Equity ratio of 1.28.
| Current Ratio | 1.17 |
| Quick Ratio | 0.71 |
| Debt / Equity | 1.28 |
| Debt / EBITDA | 10.27 |
| Debt / FCF | 79.5 |
| Interest Coverage | 0.4 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $366,361.92 |
| Profits Per Employee | $-1,579.62 |
| Employee Count | 4,396 |
| Asset Turnover | 0.4 |
| Inventory Turnover | 1.7 |
Taxes
| Income Tax | -11.29M |
| Effective Tax Rate | 61.92% |
Stock Price Statistics
The stock price has increased by -56.52% in the
last 52 weeks. The beta is 1.27, so Integra LifeSciences's
price volatility has been higher than the market average.
| Beta | 1.27 |
| 52-Week Price Change | -56.52% |
| 50-Day Moving Average | 17.33 |
| 200-Day Moving Average | 20.72 |
| Relative Strength Index (RSI) | 31.77 |
| Average Volume (20 Days) | 1,042,058 |
Income Statement
In the last 12 months, Integra LifeSciences had revenue of 1.61B
and earned -6.94M
in profits. Earnings per share was -0.09.
| Revenue | 1.61B |
| Gross Profit | 882.06M |
| Operating Income | 28.41M |
| Net Income | -6.94M |
| EBITDA | 193.29M |
| EBIT | 52.4M |
| Earnings Per Share (EPS) | -0.09 |
Full Income StatementBalance Sheet
The company has 246.38M in cash and 1.98B in
debt, giving a net cash position of -1.74B.
| Cash & Cash Equivalents | 246.38M |
| Total Debt | 1.98B |
| Net Cash | -1.74B |
| Retained Earnings | 939.91M |
| Total Assets | 4.04B |
| Working Capital | 159.56M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was 129.38M
and capital expenditures -104.42M, giving a free cash flow of 24.96M.
| Operating Cash Flow | 129.38M |
| Capital Expenditures | -104.42M |
| Free Cash Flow | 24.96M |
| FCF Per Share | 0.32 |
Full Cash Flow StatementMargins
Gross margin is 54.77%, with operating and profit margins of 1.76% and -0.43%.
| Gross Margin | 54.77% |
| Operating Margin | 1.76% |
| Pretax Margin | -1.13% |
| Profit Margin | -0.43% |
| EBITDA Margin | 12% |
| EBIT Margin | 1.76% |
| FCF Margin | 1.55% |
